Biochemical Genetics

, Volume 46, Issue 1–2, pp 64–74 | Cite as

Association of Interleukin-6, Interleukin-12, and Interleukin-10 Gene Polymorphisms with Essential Hypertension in Tatars from Russia

  • Y. R. TimashevaEmail author
  • T. R. Nasibullin
  • A. N. Zakirova
  • O. E. Mustafina


Essential hypertension is a common disease with fatal clinical complications. Epidemiological and family studies have confirmed the role of genetic predisposition in its development. Hypertensive patients have been shown to have an altered profile of pro- and anti-inflammatory cytokines. The aim of our investigation was to reveal the association of interleukin-6, interleukin-12, and interleukin-10 gene polymorphisms with essential hypertension and its clinical complications in a Tatar ethnic group from Bashkortostan, Russia. The study involved 362 hypertensive patients and 244 healthy subjects from this Tatar ethnic group (Bashkortostan, Russia). DNA was isolated from whole venous blood using phenol–chloroform extraction by the standard method. IL6 −572 G/C, IL12B 1159 C/A, and IL10 –627 C/A genotypes were typed using polymerase chain reaction followed by restriction enzyme digestion. We found that the IL10 −627 *C/*C genotype was associated with decreased risk of hypertension (OR = 0.64, P = 0.035). IL6 genotypes and allele distribution did not differ significantly between subjects with and without hypertension, but the IL6 −572 *G/*G genotype frequency was found to be significantly higher among those patients who had stroke, compared with normotensive control subjects (P = 0.036). Carriers of the IL12B 1159 *A/*A genotype had a lower risk of stroke (OR = 0.38, P = 0.028). Our study has shown the association between IL10 −627 C/A polymorphism and essential hypertension in the Tatar ethnic group from Bashkortostan, Russia. The IL10 −627*C/*C genotype was found to be protective against hypertension. We also demonstrated that hypertensive patients with the IL12B *A/*A and IL6 *G/*G genotypes had increased risk of stroke. Our results suggest a role for cytokines in cardiovascular disease development in the Tatar ethnic group, but further investigation is needed.


Essential hypertension Interleukin Polymorphism Association study 


  1. Bergholdt R, Ghandil P, Johannesen J, Kristiansen OP, Kockum I, Luthman H, Ronningen KS, Nerup J, Julier C, Pociot F (2004) Genetic and functional evaluation of interleukin-12 polymorphism (IDDM18) in families with type 1 diabetes. J Med Genet 41:e39PubMedCrossRefGoogle Scholar
  2. Blake GJ, Rifai N, Buring JE, Ridker PM (2003) Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 108:2993–2999PubMedCrossRefGoogle Scholar
  3. Brasier AR, Recinos A, Eledrisi MS (2002) Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22:1257–1266PubMedCrossRefGoogle Scholar
  4. Brull DJ, Montgomery HE, Sanders J (2001) Interleukin-6 gene −174G > C and −572G > C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 21:1458–1463PubMedCrossRefGoogle Scholar
  5. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W (2001) Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154–1159PubMedCrossRefGoogle Scholar
  6. Girndt M, Köhler H (2003) Interleukin-10: an update on its relevance for cardiovascular risk. Nephrol Dial Transplant 18:1976–1979PubMedCrossRefGoogle Scholar
  7. Grocott HP, White WD, Morris RW, Podgoreanu MV, Mathew JP, Nielsen DM, Schwinn DA, Newman MF 2005 Genetic polymorphisms and the risk of stroke after cardiac surgery. Stroke 36:1854–1858PubMedCrossRefGoogle Scholar
  8. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP (2000) Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 46:540–545PubMedCrossRefGoogle Scholar
  9. Guidelines Committee (2003) European society of hypertension/European society of cardiology guidelines for the management of arterial hypertension. J Hypertens 21(6):1011–1053CrossRefGoogle Scholar
  10. Humphries SE, Luong LA, OGG MS, Hawe E, Miller GJ (2001) The interleukin-6 −174G/C polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 22:2243–2252PubMedCrossRefGoogle Scholar
  11. Jeng JR, Wang JH, Lui WS, Chen SP, Chen MY, Wu MH, Hsu WL, Lin SZ (2005) Association of interleukin-6 G-174C polymorphism and plasma plasminogen activator inhibitor-1 level in Chinese patients with and without hypertension. Am J Hypertens 18:517–522PubMedCrossRefGoogle Scholar
  12. Johns M, Paulus-Thomas J (1989) Purification of human genomic DNA from whole venous blood using proteinase K treatment followed by phenol-chloroform extraction. Annal Biochem 180:276–278CrossRefGoogle Scholar
  13. Kofler S, Nickel T, Weis M (2005) Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci 108:205–213PubMedCrossRefGoogle Scholar
  14. Losito A, Kalidas K, Santoni S, Jeffery S (2003) Association of interleukin-6 −174 promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 64(2):616–622PubMedCrossRefGoogle Scholar
  15. Mombouli JV, Vanhoutte PM (1999) Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 31:61–74PubMedCrossRefGoogle Scholar
  16. Morahan G, Huang DX, Ymer SI, Cancilla MR, Stephen K, Dabadghao P, Werther G, Tait BD, Harrison LC, Colman PG (2001) Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nat Genet 27:218–221PubMedCrossRefGoogle Scholar
  17. Mostafa ME, Chollet-Martin S, Oudghiri M et al (2001) Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc Res 49:882–890CrossRefGoogle Scholar
  18. Ross R (1999) Atherosclerosis, an inflammatory disease. N Engl J Med 340:115–126PubMedCrossRefGoogle Scholar
  19. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al (2000) Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101:1372–1378PubMedGoogle Scholar
  20. Staessen JA, Wang J, Bianchi G, Birkenhager WH (2003) Essential hypertension. Lancet 361:1629–1641PubMedCrossRefGoogle Scholar
  21. Wallace C, Xue M-Z, Newhouse SJ et al (2006) Linkage analysis using co-phenotypes in the BRIGHT study reveals novel potential susceptibility loci for hypertension. Am J Hum Genet 79:323–331PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Y. R. Timasheva
    • 1
    Email author
  • T. R. Nasibullin
    • 1
  • A. N. Zakirova
    • 2
  • O. E. Mustafina
    • 1
  1. 1.Institute of Biochemistry and Genetics, Ufa Scientific CentreRussian Academy of ScienceUfaRussia
  2. 2.Department of CardiologyBashkir State Medical UniversityUfaRussia

Personalised recommendations